PCOS / PMOS Hair Loss — Female Pattern Androgenetic Alopecia

Hair loss affects 20–30% of women with PCOS and is one of the most distressing symptoms of the condition. Understanding the mechanism — DHT-driven follicular miniaturization — and the evidence behind each treatment (minoxidil, spironolactone, PRP, iron) is essential to choosing the right approach and setting realistic expectations.

Why PCOS causes hair loss

Hair loss in PCOS is primarily driven by dihydrotestosterone (DHT), the most potent androgenic hormone in scalp tissue. In the scalp, testosterone is converted to DHT by the enzyme 5-alpha-reductase type II, which is expressed at high levels in scalp follicles. DHT binds to androgen receptors within the dermal papilla — the vascularized structure at the base of each hair follicle — and triggers a process called follicular miniaturization.

Miniaturization is a progressive shortening of the anagen (growth) phase and miniaturization of the hair shaft diameter over successive hair cycles. A follicle that once produced a terminal hair (thick, pigmented, long) gradually produces thinner, shorter, and less pigmented vellus-type hairs, then eventually ceases production. Once a follicle is fully miniaturized and replaced by fibrous tissue, hair loss in that location is permanent.

The key variable is genetic sensitivity of the scalp follicles to DHT — this is encoded in androgen receptor polymorphisms (particularly the AR gene on the X chromosome). Two women with identical circulating androgen levels can have dramatically different hair loss experiences depending on their genetic androgen receptor sensitivity. This explains why hair loss does not affect all women with PCOS equally, and why it can occur even in PCOS women with only mildly elevated androgens.

In PCOS, elevated circulating testosterone and DHEA-S increase the substrate available for DHT conversion in scalp tissue. Insulin resistance further elevates androgens by reducing SHBG (sex hormone binding globulin), which increases free — biologically active — testosterone available to scalp androgen receptors. Sources: Trüeb RM 2002 (Dermato-Endocrinology); Famenini S et al. 2015 (International Journal of Dermatology).

The 3 types of hair loss in PCOS / PMOS

1. Female Pattern Hair Loss (FPHL) — androgenetic alopecia. This is the classic PCOS-associated hair loss pattern. It is progressive and chronic, characterized by thinning at the vertex (crown of the head) and widening of the central part line, following the Ludwig classification (Grade I: minimal thinning; Grade II: moderate widening; Grade III: severe thinning with visible scalp). Unlike male pattern baldness, FPHL typically does not cause complete frontal hairline recession. Without treatment, it progresses slowly over years to decades.

2. Telogen effluvium. A sudden diffuse shedding of 100–300 hairs per day (compared to the normal 50–100), affecting the entire scalp rather than a specific pattern. It is triggered by acute physiological stress: severe illness, major surgery, dramatic caloric restriction, postpartum hormonal change, sudden iron or protein deficiency, or acute psychological stress. The mechanism is a synchronization of hair follicles into the telogen (resting/shedding) phase simultaneously. Telogen effluvium in PCOS can be triggered by the same stressors as in the general population, but nutritional deficiencies (particularly iron, which is common in PCOS women with heavy periods) are an especially frequent precipitant. It is fully reversible within 3–6 months of addressing the underlying cause.

3. Alopecia areata. An autoimmune condition characterized by circumscribed circular patches of hair loss, rather than diffuse thinning. Alopecia areata has a slightly increased prevalence in PCOS compared to the general population, consistent with the broader autoimmune dysregulation seen in some PCOS phenotypes. It requires distinct immunomodulatory treatment approaches (topical or injected corticosteroids, JAK inhibitors in severe cases). Source: BJD (British Journal of Dermatology) 2024 review on hair disorders in PCOS.

Essential tests — ferritin is key

Before initiating any hair loss treatment, a targeted blood panel is essential to rule out correctable contributors and confirm the diagnosis. The most important tests are:

Ferritin (serum iron stores) is the single most clinically impactful test in PCOS women with hair loss. Women with PCOS who have heavy or prolonged menstrual bleeding are at elevated risk of iron deficiency. Ferritin below 30–40 ng/mL is classified as deficiency by most standards. A growing body of dermatology literature suggests that ferritin below 70 ng/mL represents an insufficiency state that can independently worsen both telogen effluvium and androgenetic alopecia, even in the absence of frank anemia. Correcting iron deficiency is simple and inexpensive — yet frequently missed.

Complete blood count (CBC) identifies frank anemia (low hemoglobin) but is an insensitive early marker — anemia appears only after stores are substantially depleted. Ferritin is a better early indicator.

Vitamin D — deficiency is extremely common in PCOS (50–80% of women depending on population) and vitamin D receptors (VDR) are expressed in hair follicles. Severe deficiency is associated with hair cycle abnormalities. Correct deficiency before attributing hair loss solely to androgens.

Serum zinc, TSH (hypothyroidism is a common cause of diffuse hair loss and is more prevalent in PCOS), full PCOS hormonal panel (total and free testosterone, DHEA-S, SHBG, prolactin — elevated prolactin also causes hair loss independently).

Trichoscopy (dermoscopy of the scalp) is a rapid, non-invasive office procedure that differentiates FPHL, telogen effluvium, and alopecia areata within minutes based on specific dermoscopic patterns. It is the preferred first assessment tool for dermatologists. Sources: BJD 2024; Trüeb 2002; Famenini 2015.

Topical treatment — minoxidil 5%

Minoxidil 5% (available as solution or foam) is the reference topical treatment for FPHL and the only FDA-approved topical medication for female hair loss (at the 2% and 5% concentrations). Its mechanism of action in hair loss is not fully understood but involves perifollicular vasodilation (improving follicular blood supply and nutrient delivery), potassium channel opening in keratinocytes, stimulation of vascular endothelial growth factor (VEGF), and extension of the anagen (growth) phase.

Application: 1 mL of 5% solution applied twice daily to dry scalp with a dropper, or half-dose foam once daily. The scalp should be towel-dried before application. Allow to dry for 30 minutes before styling or going to bed. Consistent daily use is essential — irregular use diminishes efficacy significantly.

Efficacy in clinical trials: significant improvement in hair count and shaft diameter versus placebo, with approximately 35–40% of women showing meaningful density improvement in properly conducted RCTs. Response varies by individual and FPHL severity — earlier stages respond better. Cochrane 2017 review on topical minoxidil in women confirmed significant benefit over placebo for FPHL.

Key points about side effects and expectations: an initial increase in shedding during the first 1–3 months of use is normal and expected — it represents a synchronization of follicles entering anagen and pushing out old telogen hairs. This is a sign of activity, not treatment failure. The benefit must be maintained with continued use — stopping minoxidil leads to reversal of gains within 3–6 months as follicles return to their pre-treatment state. Mild scalp irritation is common, especially with the solution (propylene glycol vehicle). The foam formulation causes less irritation. Rare facial hypertrichosis (fine hair on temples or forehead) is more common with the solution and largely resolves by switching to foam or reducing contact with the face. Sources: Cochrane 2017; Blumeyer et al. 2011 European Dermatology Forum guidelines.

Systemic treatments — spironolactone and other anti-androgens

Spironolactone (50–200 mg/day) is a potassium-sparing diuretic with significant peripheral anti-androgenic properties. In the context of PCOS hair loss, its primary mechanism is competitive blockade of androgen receptors at the scalp hair follicle, preventing DHT-receptor binding and interrupting the miniaturization process. At doses above 100 mg/day, it also modestly inhibits androgen biosynthesis.

Evidence for FPHL: a growing body of evidence including the BJD 2024 systematic review confirms improvement in hair density scores and slowing of progression with spironolactone in women with FPHL, including PCOS-related FPHL. Response is dose-dependent — most protocols start at 50 mg/day and titrate to 100–200 mg/day based on response and tolerance.

Monitoring requirements: serum potassium at 4 weeks after starting (risk of hyperkalemia, especially if combining with ACE inhibitors, NSAIDs, or potassium supplements), then every 6 months during stable treatment. Blood pressure monitoring (it has antihypertensive effects — beneficial if hypertensive, requires adjustment if already hypotensive). Mandatory reliable contraception — spironolactone is teratogenic for male fetuses (feminization of male genitalia). This is an absolute requirement, not optional.

Finasteride (1–5 mg/day) and dutasteride (0.1–0.5 mg/day) are 5-alpha-reductase inhibitors that prevent testosterone-to-DHT conversion. They are highly effective in men. In women, they are used off-label primarily in postmenopausal women where teratogenicity is not a concern. In premenopausal women of childbearing potential, the teratogenic risk for male fetuses (incomplete masculinization) is severe — they should only be used with absolutely reliable contraception and after thorough informed consent. Not typically first choice in reproductive-age PCOS women. Sources: BJD 2024; Shapiro 2000; Finasteride in women — European Hair Research Society guidelines.

Treatment comparison — evidence and practical guide

Sources: Cochrane 2017 (minoxidil); BJD 2024 (spironolactone); Gupta 2024 (PRP); European Hair Research Society guidelines.

PRP and mesotherapy — 2024 data

Platelet-rich plasma (PRP) involves drawing a small amount of the patient's blood, centrifuging it to concentrate platelets, and injecting the resulting platelet-rich fraction into the scalp. Platelets release a cocktail of growth factors — VEGF (vascular endothelial growth factor), PDGF (platelet-derived growth factor), IGF-1, TGF-β — that may stimulate dormant follicles and extend the anagen phase.

The Cochrane 2024 meta-analysis (Gupta et al., 12 studies, 560 patients) found statistically significant improvement in hair count per cm² and hair shaft diameter with PRP compared to placebo injections or no treatment. However, high heterogeneity between studies — due to differences in PRP preparation protocols, centrifugation speed, platelet concentration, injection frequency, and patient populations — limits the strength of conclusions. No standardized PRP preparation protocol has been established.

In practice: PRP is best positioned as an adjunct to established treatments (minoxidil + spironolactone), not as a replacement. It is not covered by any insurance system. Cost ranges from $200–400 per session; a standard initial course is 3–4 monthly sessions, often followed by maintenance every 3–6 months. The invasive nature (multiple scalp injections per session) and cost mean it is appropriate for motivated patients who have not achieved adequate results with topical and systemic treatments alone, or who prefer to avoid systemic medications. Sources: Gupta et al. 2024 Cochrane meta-analysis; BJD 2024.

When to see a dermatologist for PCOS hair loss

Self-diagnosis of hair loss type based on pattern alone is unreliable and frequently leads to incorrect self-treatment. A dermatology evaluation is strongly recommended in any of the following situations: hair shedding exceeding 100 hairs per day for more than 3 months; visible density loss at the vertex or part line noticeable to yourself or others; rapid thinning over a period of weeks (suggesting an acute trigger rather than gradual FPHL); circumscribed bald patches (suggesting alopecia areata); scalp pruritus, scaling, or inflammation (suggesting a scarring alopecia or seborrheic component requiring specific treatment); or if self-initiated treatment with minoxidil for 6 months shows no response.

A dermatologist will perform trichoscopy (dermoscopic scalp examination) to characterize the hair loss pattern precisely — FPHL, telogen effluvium, areata, and scarring alopecias each have distinct dermoscopic signatures. In ambiguous cases, a 4 mm punch biopsy of the affected area may be performed to determine the presence and degree of follicular miniaturization, inflammation, or fibrosis. This guides treatment selection and prognosis. Treatment of PCOS hair loss is most effective when started early, before significant permanent follicular loss has occurred. Sources: Tosti A, BJD 2024; International Society of Hair Restoration Surgery guidelines.

Frequently asked questions about PCOS hair loss

Is PCOS-related hair loss reversible?

Partially. FPHL can be stopped and partially reversed with early treatment — minoxidil and anti-androgens preserve functional follicles and can improve density. Very long-standing miniaturization may be permanent. Telogen effluvium is fully reversible once the underlying cause (deficiency, stress, illness) is treated, typically within 3–6 months.

Should I check ferritin before treating hair loss?

Yes — absolutely. Ferritin below 30–40 ng/mL (some experts say below 70 ng/mL) potentiates hair loss. PCOS women with heavy periods are at elevated risk of iron deficiency. Correcting it is simple and can significantly improve hair loss without any other intervention.

Can I use minoxidil with PCOS?

Yes. Minoxidil 5% is the reference topical treatment for FPHL in PCOS. It complements but does not replace treatment of underlying hyperandrogenism. Allow at least 6 months before assessing results. Stopping minoxidil reverses gains within 3–6 months.

Does spironolactone help PCOS hair loss?

Yes — spironolactone 50–200 mg/day blocks androgenic receptors in scalp follicles, slowing FPHL progression and improving density. Documented in BJD 2024. Requires potassium monitoring and mandatory contraception (teratogenic for male fetuses).

Does PRP work for androgenetic alopecia?

Cochrane 2024 (12 studies, 560 patients) found significant improvement in hair density with PRP versus placebo. Positioned as an adjunct, not a replacement for established treatments. Not covered by insurance — $200–400 per session, typically 3–4 sessions.

What is the difference between telogen effluvium and androgenetic alopecia?

Telogen effluvium: sudden diffuse shedding (100–300 hairs/day), reversible within 3–6 months of treating the cause. FPHL: progressive chronic thinning at vertex and central part, caused by follicular miniaturization from DHT — partially reversible with treatment but irreversible once follicles are fully scarred.

General information only. Hair loss diagnosis and treatment should be supervised by a dermatologist or healthcare provider. Sources: Trüeb RM 2002 (Dermato-Endocrinology); Famenini S 2015 (Int J Dermatology); Cochrane 2017 (minoxidil women); BJD 2024 (spironolactone and FPHL); Gupta MK 2024 (PRP Cochrane meta-analysis). See our scientific sources page.